Institute of Cellular Medicine, Newcastle University Medical School, Newcastle-upon-Tyne, UK.
Transpl Int. 2011 Jun;24(6):588-95. doi: 10.1111/j.1432-2277.2011.01240.x. Epub 2011 Mar 8.
We compared functional ability and symptom severity in liver transplant recipients and matched chronic liver disease (CLD) and community controls. A total of 103/140 consecutive liver transplant recipients from a single centre (73%) and matched controls completed the patient-reported functional outcome measure: Patient-Reported Outcomes Measurement Information System, Health Assessment Questionnaire (PROMIS HAQ). Symptoms frequently seen in CLD were quantified by (i) Fatigue Impact Scale (FIS), (ii) Orthostatic Grading Scale (OGS: autonomic dysfunction), (iii) Cognitive Failures Questionnaire (CFQ) and (iv) Epworth Sleepiness Scale (ESS: Daytime somnolence). Liver transplant recipients exhibited significant reduction in function (P<0.0001) across all domains of the PROMIS HAQ suggesting that functional impairment is broad-based. Seventy-seven per cent of all postliver transplants identified some difficulty with activities of daily living. There was no relationship between PROMIS HAQ and liver biochemistry (r²=0.04, P=NS) or time since transplant (r² =0.1, P=NS). Elevation in PROMIS HAQ (and therefore functional impairment) strongly associated with symptoms, particularly fatigue, cognitive impairment and daytime somnolence. Fatigue severity was independently associated with functional impairment (FIS) (Beta 0.727, P < 0.0001). Symptoms or functional ability was not different between liver transplant recipients and matched chronic liver disease controls. Although survival postliver transplantation is improving, our cross-sectional study suggests that functional ability may not improve postliver transplantation. Further study is warranted to address the mechanisms responsible for post-transplant functional impairment and to develop effective rehabilitation regimes to maximize function following liver transplantation.
我们比较了肝移植受者与匹配的慢性肝病(CLD)和社区对照者的功能能力和症状严重程度。来自一个中心的 140 例连续肝移植受者中的 103 例(73%)和匹配的对照者完成了患者报告的功能结局测量:患者报告结局测量信息系统,健康评估问卷(PROMIS HAQ)。通过以下方法量化 CLD 中常见的症状:(i)疲劳影响量表(FIS),(ii)直立分级量表(OGS:自主神经功能障碍),(iii)认知失败问卷(CFQ)和(iv)Epworth 嗜睡量表(ESS:白天嗜睡)。肝移植受者在 PROMIS HAQ 的所有领域均表现出功能显著下降(P<0.0001),表明功能障碍广泛存在。所有肝移植后的患者中有 77%在日常生活活动中存在某些困难。PROMIS HAQ 与肝生化(r²=0.04,P=NS)或移植后时间(r²=0.1,P=NS)之间没有关系。PROMIS HAQ 的升高(因此功能障碍)与症状,特别是疲劳、认知障碍和白天嗜睡强烈相关。疲劳严重程度与功能障碍(FIS)独立相关(Beta 0.727,P<0.0001)。肝移植受者与匹配的慢性肝病对照者之间的症状或功能能力无差异。尽管肝移植后的生存率正在提高,但我们的横断面研究表明,肝移植后功能能力可能不会改善。需要进一步研究以确定导致移植后功能障碍的机制,并制定有效的康复方案,以最大限度地提高肝移植后的功能。